Barclays Maintains Overweight on Coherus BioSciences, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad has maintained an Overweight rating on Coherus BioSciences (NASDAQ:CHRS) but lowered the price target from $8 to $7.
October 23, 2023 | 3:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays has maintained an Overweight rating on Coherus BioSciences but lowered the price target from $8 to $7.
The news is directly related to Coherus BioSciences. The maintained Overweight rating indicates a positive outlook, but the lowered price target could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100